Tarceva 150 mg (Tablet)

Unit Price: ৳ 3,599.76 (3 x 10: ৳ 107,992.80)
Strip Price: ৳ 35,997.60

Medicine Details

Category Details
Generic Erlotinib
Company Roche bangladesh ltd
Also available as

Therapeutic Class

  • Targeted Cancer Therapy

Indications

  • First-line treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletions or exon 21 substitution mutations
  • Maintenance treatment of locally advanced or metastatic NSCLC after four cycles of platinum-based first-line chemotherapy
  • Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen
  • First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer in combination with gemcitabine

Description

  • Chemical name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine
  • Reversibly inhibits EGFR kinase activity
  • Higher binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations than wild-type receptor

Dosage & Administration

  • Recommended daily dose for NSCLC: 150 mg on an empty stomach
  • Recommended daily dose for Pancreatic Cancer: 100 mg once daily in combination with gemcitabine
  • Dose reduction for severe reactions with CYP3A4 inhibitors
  • Dose increment for concurrent cigarette smoking or CYP3A4 inducers

Interaction

  • Interaction with coumarin-derived anticoagulants leading to increased International Normalized Ratio (INR) and bleeding adverse reactions
  • Metabolized predominantly by CYP3A4
  • Effects of co-treatment with CYP3A4 inhibitors and inducers
  • Effects of drugs affecting gastric pH on Tarceva exposure

Side Effects

  • Common adverse reactions: rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, vomiting
  • Serious adverse reactions including Interstitial Lung Disease (ILD), Renal Failure, and Gastrointestinal Perforation

Pregnancy & Lactation

  • Pregnancy category D
  • Potential for fetal harm
  • Unknown presence in human milk

Precautions & Warnings

  • Risk of Interstitial Lung Disease (ILD)
  • Monitoring of renal function and electrolytes
  • Monitoring of liver testing
  • Discontinuation in cases of ILD, renal toxicity, hepatic impairment, gastrointestinal perforations, and skin disorders

Use in Special Populations

  • Safety and effectiveness in pediatric patients not established
  • No overall differences in safety or efficacy in subjects aged 65 and older

Overdose Effects

  • Tolerance of single oral doses up to 1,000 mg in healthy subjects
  • Poor tolerance of repeated twice-daily doses above recommended levels
  • Possible severe adverse reactions such as diarrhea, rash, and liver transaminase elevation

Storage Conditions

  • Store at a temperature not exceeding 30°C
  • Protect from light and moisture

Related Brands